Mersana is rewriting the rules for ADC therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives.

Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particular cancer. We engineer ADCs to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Our management team has the experience, expertise and passion to translate the promise of our Fleximer platform into therapies that make a dramatic difference for patients. They bring to bear deep expertise in the critical disciplines of biology, chemistry, polymer science, drug development and oncology, and the collaborative leadership style needed to build a company of exceptional value.

Anna Protopapas
President and Chief Executive Officer

Ms. Protopapas joined Mersana in March 2015, bringing a substantial track record of executive leadership and business experience in the biotech industry. Prior to Mersana, Ms. Protopapas was President of Millennium, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business. Ms. Protopapas also served as the Executive Vice President of Global Business Development for Takeda Pharmaceuticals where she was responsible for global acquisitions, partnering, licensing and venture investing. In this role, she led Takeda’s $12 billion acquisition of Nycomed, a critical step in the company’s globalization. Ms. Protopapas was a member of Takeda’s executive committee and was elected a corporate officer in 2011. Earlier, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader. She was instrumental in the sale of Millennium to Takeda for $8.8 billion. She earned her bachelor’s degree in science and engineering from Princeton University, a master’s in chemical engineering practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.

Donald A. Bergstrom
M.D., Ph.D.
Chief Medical Officer

Dr. Bergstrom joined Mersana in January 2014, bringing a decade of industry experience in translational medicine and drug development. Prior to Mersana, Dr. Bergstrom spent four years as Associate Vice President and Global Head of Translational and Experimental Medicine at Sanofi Oncology, where he built a global team of laboratory and clinical scientists focused on defining and executing scientifically rigorous early development strategies. Dr. Bergstrom represented Sanofi in the governance of a number of collaborations with academic and industry partners. Prior to Sanofi, Dr. Bergstrom spent six years at Merck Research Labs in roles of increasing responsibility in the Clinical Molecular Profiling, Oncology Clinical Research and Experimental Medicine Oncology groups. Dr. Bergstrom completed his M.D. and residency at the University of Washington and his Ph.D. and post-doctoral training at the Fred Hutchinson Cancer Research Center.

Wayne Foster
Vice President of Finance

Mr. Foster joined Mersana in February 2012, bringing more than 20 years of financial management and public accounting experience. Prior to Mersana, he served for nine years as Senior Director of Finance at Tolerx, where he was responsible for a wide variety of finance functions during a period of significant growth for the company. He spent nine years as a Senior Manager at Arthur Andersen, where he specialized in emerging life science and technology companies. He earned his B.B.A. in Accounting from the University of Massachusetts Amherst.

Radha Iyengar
Vice President, Legal Operations

Radha Iyengar joined Mersana in 2010 as a consultant and became a full time employee in 2012 as Executive Director, Intellectual Property. Dr. Iyengar brings nearly 30 years of intellectual property, licensing and R&D experience to her current role as Vice President, Legal Operations.  Prior to Mersana, Dr. Iyengar held the position of Senior Director, Intellectual Property with Magen Biosciences, Inc., where she played a key role in the Eli Lilly in-licensing agreement. Dr. Iyengar also held a series of positions with increasing responsibility at Nitromed, Inc., including Senior Director, Intellectual Property and Technology Licensing. During the course of her tenure at Nitromed, Inc., Dr. Iyengar was responsible for a growing intellectual property portfolio of 360+ patents worldwide, as well as serving as a member of the company’s R&D Committee. Dr. Iyengar holds a Ph.D. in Chemistry from Brown University, an M.Sc. in Chemistry from the Indian Institute of Technology Kanpur, and a B.Sc (Hons)., in Chemistry from Lady Brabourne College, Kolkatta. She is also a U.S. Patent Agent. 

Eva M. Jack
Chief Business Officer

Ms. Jack joined Mersana in November 2013, bringing a wealth of business development and financial experience in the biotech industry. Prior to Mersana, she served as an advisor to biotech companies and investors on business and financing strategies. From 2010 to 2012, she served as Chief Business Officer of Pulmatrix. She also spent six years at MedImmune, the worldwide biologics unit of AstraZeneca, as Managing Director of MedImmune Ventures, overseeing investments in private biotechnology companies, and as a Director in MedImmune’s Business Development group. Earlier in her career, Ms. Jack held a variety of positions at Intel Corp. in venture investments, corporate strategy and public policy. Ms. Jack received a B.A. from the University of Virginia and a master’s in health sciences from The Johns Hopkins University.  Additionally, she is a volunteer puppy raiser for Canine Companions for Independence®, a non-profit organization that enhances the lives of people with disabilities by providing highly trained assistance dogs.

Donna Jarlenski
Vice President, Clinical Operations

Donna Jarlenski joined Mersana in July 2015, bringing over twenty years of clinical research, development and operations management experience. With a diverse background, Ms. Jarlenski broadens the capacity of Mersana bringing extensive experience in Ph 1 through 3 international clinical trial initiation and management, including data management, financial controls, and medical writing. She also brings extensive experience with GCP oversight, vendor management, and process development.   Immediately prior to joining Mersana Ms. Jarlenski served as Vice President, Clinical Operations and Program Management for Aileron Therapeutics. Additionally, she has held senior clinical management positions at Vertex Pharmaceuticals (Senior Director, Clinical Development Execution, Global Medicines Development & Affairs), Momenta Pharmaceuticals (Senior Director, Development Operations, Clinical), and TolerX, Inc. (Vice President, Clinical Development & Operations).  She has held directorships at Sepracor, Inc., and Purdue Pharmaceuticals, Ltd.  Before entering the drug development arena in the early 1990s, Ms. Jarlenski began her career as a bench scientist and subsequently underwent further training to work as a physical therapist.  She earned her bachelor’s degree in microbiology from The Pennsylvania State University and master degree from Quinnipiac University (Organizational Leadership).   Since 2011, Ms. Jarlenski has been a registered Project Management Professional.

Michael Kaufman
Senior Vice President of Chemistry, Manufacturing and Controls

Dr. Kaufman joined Mersana in February 2016, bringing more than two decades of experience in process development, scale-up, formulation and supply chain management across multiple therapeutic modalities, including immunoconjugates. Prior to Mersana, Dr. Kaufman served as Biogen’s Vice President, Technical Development, where he provided technical leadership for all products from preclinical to commercial stage. Dr. Kaufman also spent 10 years at Millennium Pharmaceuticals, most recently as Vice President, Pharmaceutical Sciences, leading all aspects of chemistry, manufacturing and controls. Dr. Kaufman began his pharmaceutical career at Merck and Co., Inc., spending 15 years in various roles of increasing responsibility. Dr. Kaufman holds a Ph.D. in Physical Organic Chemistry from the University of California, Berkeley, and a B.S. in Chemistry from State University of New York, Stony Brook. He was a post-doctoral fellow at Louisiana State University and an instructor at the University of California.


Timothy B. Lowinger
Chief Scientific Officer

Dr. Lowinger joined Mersana in 2008, bringing nearly 15 years of global scientific leadership and drug discovery experience in the pharmaceutical and biotech industries. Over the course of his career at Bayer Pharmaceuticals in the US, Japan and Germany, he contributed to the discovery of more than 15 preclinical and clinical drug candidates in the areas of oncology, asthma, inflammation, virology, obesity and diabetes. Most notably, Dr. Lowinger is a co-inventor of the pioneering anti-angiogenic agent Nexavar (sorafenib), approved for the treatment of renal and hepatocellular cancer, as well as Stivarga (regorafenib), approved for the treatment of metastatic colorectal cancer. Dr. Lowinger has published more than 40 scientific papers and is a co-inventor on more than 40 patents. He has a B.Sc. (Hons.) in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia and was a Merck Postdoctoral Fellow at the Ohio State University in the lab of Professor Leo A. Paquette. He currently serves on the Scientific Advisory Board of Keystone Symposia.

David Mott
General Partner, New Enterprise Associates

Mr. Mott joined Mersana’s board as Chairman in July 2012. He is a General Partner at New Enterprise Associates, where he leads the healthcare investing practice. Before joining NEA, he spent 16 years at MedImmune in roles of increasing responsibility, including Chief Operating Officer, Chief Financial Officer and CEO, building the company from a venture-backed startup into one of the top five biotechnology companies in the world, He led the sale of MedImmune to AstraZeneca in 2007 for $15.6 billion, and at the time of his departure in 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Mr. Mott is also Chairman of 3-V Biosciences, Cydan, Prosensa, TESARO and Zyngenia and a director of Ardelyx, Edimer Pharmaceuticals and Epizyme. He received his B.A. from Dartmouth College.

Thomas R. Beck
Executive Partner, F-Prime Capital

Dr. Beck is an Executive Partner at F-Prime Capital. Before joining F-Prime in 2007, he served as President and Chief Operating Officer at Dyax Corp. During his more than 30-year career in the pharmaceutical and biotech industries, Dr. Beck has held a number of leadership positions at companies, including UCB Pharma, CytoMed and Enzytech. He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development. Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. Dr. Beck also serves on the Board of Directors of NeuroTherapeutics Pharma and Vicept Therapeutics. He received his B.S. degree from Yale University and his M.D. from Cornell University.

Andrew Hack
M.D., Ph.D.
Chief Financial Officer, Editas

Andrew joined Editas Medicine as CFO in July 2015. Previously, he served as a portfolio manager at Millennium Management, where he ran a healthcare fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Andrew was an analyst Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career covering the biotechnology sector at Banc of America Securities. In addition, Andrew was a co-founder of Reify Corporation, a life science tools and drug discovery company.

Andrew received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D., was named the inaugural Frank Family Scholar, and received awards from the American Heart Association and the American Society for Cell Biology.

Kristen M. Hege
Corporate Vice President, Celgene

Dr. Hege is the Corporate Vice President, Translational Development, Hematology & Oncology, San Francisco Site Head, and an Executive Leader for the Immuno-Oncology Center of Excellence at Celgene. Prior to this, she served as Acting Chief Medical Officer for Aragon, Theraclone, Cellerant and the Cancer Vaccine Company and spent 14 years at Cell Genesys ultimately leading Clinical Research and Development. In addition to her industry roles, Dr. Hege holds an active clinical faculty appointment at UCSF as a Professor of Medicine in Hematology/Oncology. She serves on the Board of Directors of the Society for Immunotherapy of Cancer, the Strategic Advisory Group for the Parker Institute for Cancer Immunotherapy and was recognized by FierceBiotech as one of the top 12 women in Biopharma in 2015.  Dr. Hege received her BA summa cum laude from Dartmouth, MD from the University of California, San Francisco (UCSF), internal medicine training at Harvard and subspecialty training in hematology/oncology from UCSF.

Elaine V. Jones
Executive Director, Pfizer Venture Investments

Dr. Jones is an Executive Director at Pfizer Venture Investments. She is responsible for making and managing venture investments for Pfizer and currently manages its investments in Aquinox Pharmaceuticals, Flexion Therapeutics, Merus B.V. and NeuroTherapeutics Pharma. Dr. Jones brings a decade of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development. Prior to joining Pfizer, Dr. Jones was a General Partner with EuclidSR Partners. She began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund. Before that, she was Director of Scientific Licensing for SmithKline Beecham and a research scientist in SmithKline Beecham Pharmaceutical R&D. Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.

Sara Nayeem
Partner, New Enterprise Associates

Dr. Nayeem is a Principal at New Enterprise Associates, where she focuses on investments in biopharmaceutical companies. She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has been involved in NEA’s investments in 3-V Biosciences and Prosensa. She also assists with management of several of NEA's publicly traded portfolio companies. Prior to joining NEA in 2009, Dr. Nayeem was an Associate with Merrill Lynch’s Global Healthcare Group, advising biotechnology, pharmaceutical and medical device companies on mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. Dr. Nayeem received her AB in Biological Sciences from Harvard University and her M.D. and M.B.A. from Yale University.

Anna Protopapas
Chief Executive Officer

Ms. Protopapas joined Mersana in February 2015, bringing a substantial track record of executive leadership and business experience in the biotech industry. Prior to Mersana, Ms. Protopapas was President of Millennium, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business, and a member of Takeda’s Executive Committee. In four years as an executive officer at Takeda, Ms. Protopapas served in various roles of increasing responsibility, including as the Executive Vice President of Global Business Development responsible for global acquisitions, partnering, licensing and venture investing. In this role, she was instrumental in developing and executing a business plan to globalize Takeda and led the company’s $12 billion acquisition of Nycomed. Prior to Takeda’s acquisition of Millennium in 2008, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader. She earned her bachelor’s degree in science and engineering from Princeton University, a master’s in chemical engineering practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.

Christoph Lengauer
Ph.D., MBA
Executive Vice President, Blueprint Medicines

Christoph Lengauer is executive vice president at Blueprint Medicines. He has a proven record in cancer drug discovery, including contributing to the development of more than 20 drugs that reached first-in-human clinical trials and three FDA-approved medicines. Christoph joined Blueprint Medicines from Sanofi, where he was vice president and global head of oncology drug discovery and preclinical development. Before joining Sanofi, he was executive director and senior unit head of oncology discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine. As part of his research, Christoph discovered that all cancers are genetically unstable and was involved in the identification of several cancer driver genes. He has authored more than one hundred scientific articles published in top-tier scientific journals, including Cell, Nature and Science.

In 2015, Christoph built the German Accelerator Life Sciences (GALS) in Boston, which provides high-end strategic consulting to young German biotechs so they can more easily succeed in becoming strong companies and introduce their products to the global market. Christoph joined Third Rock Ventures as a venture partner in 2016 and focuses on the formation of companies discovering and developing novel therapeutics.

Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg in Germany, and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School. Christoph holds adjunct associate professor positions at Johns Hopkins University and Harvard University. He has received numerous awards, including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award and a V Foundation scholarship. Christoph was awarded the Novartis Oncology President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars.

Ronald T. Borchardt
Distinguished Professor Emeritus in School of Pharmacy - Pharmaceutical Chemistry, The University of Kansas

Ronald T. Borchardt is a Distinguished Professor Emeritus of Pharmaceutical Chemistry at The University of Kansas- Lawrence. Professor Borchardt’s research interests have focused on various aspects of both drug discovery and drug development. He is the author or co-author of more than 500 scientific publications, Editor of ten books, and the Series Editor of 23 books. During his academic career Professor Borchardt has received numerous national and international awards and honors for his teaching and research accomplishments, including honorary degrees from University of Uppsala, Katholieke Universiteit Leuven (KU Leuven) and the University of Copenhagen. Professor Borchardt has been the Editor-in-Chief of the Journal of Pharmaceutical Sciences since 2001. 

Howard A "Skip" Burris III
President, Clinical Operations and Chief Medical Officer, Sarah Cannon

Howard A "Skip" Burris III, MD serves as chief medical officer and president of Sarah Cannon's clinical operations, HCA's global cancer institute.  In his roles, he leads clinical strategy and drug development initiatives, which includes the overseeing physician-led, patient-centric integrated cancer services. Additionally, Dr. Burris is an associate with Tennessee Oncology, PLLC.

In 1997, Dr. Burris established the first community-based phase 1 drug development program in Nashville which became Sarah Cannon Research Institute. Among his many notable accomplishments, he led the first-in-human studies for many now-approved drugs that have changed the standard of care for several types of cancers including docetaxel and ado-trastuzumab emtansine in breast cancer and everolimus in kidney cancer. Burris has also authored more than 300 publications and more than 450 abstracts. In 2014, he was named a Giant of Cancer Care during the ASCO annual meeting.

Dr. Burris received his medical degree from the University of South Alabama in 1985, and performed his residency and fellowship in hematology/oncology at Brooke Army Medical Center in San Antonio, Texas. While there, he served as director of clinical research at the Institute for Drug Development of The Cancer Therapy and Research Center, and was an associate professor at The University of Texas Health Science Center. He has served on the ASCO Board of Governors, ASCO Audit Committee, and chairman of one ASCO nominating committee.

David Colcher
Professor, Immunology, Director, Small Animal Imaging Core, Research Radiopharmacy, and Division of Radioimmunotherapy, City of Hope

David Colcher joined the City of Hope in November 2002.  Dr. Colcher received his S.B.L.S. degree from MIT and his PhD from Columbia University.  He has 35 years of experience using radiolabeled monoclonal antibodies for preclinical and clinical use, both in vitro and in vivo in model systems and in numerous clinical studies.  Dr. Colcher has been a pioneer in the field of developing antibodies to tumor associated antigens.  In 1980 while at the National Cancer Institute, where he worked with Jeffrey Schlom, he developed a number of antibodies to tumor associated antigens that are well recognized in the field.  This translational work resulted in the submission of a number of INDs resulting clinical trials for the localization and treatment of solid tumors.  In 1990 he moved to the University of Nebraska Medical Center where he was a Professor in the Departments of Pathology and Microbiology, Radiology and at the Eppley Institute as well as being a Member of the NCI designated Cancer Center.  While at UNMC he was a Project Leader and Core Director of a GI SPORE and received funds from the Department of Energy for the development of engineered antibody constructs for radioimmunotherapy.  In 1999 he moved to a biotechnology company where he spent over 3 years.  There he was involved in the manufacturing and Quality Control of a radiolabeled antibody for the treatment of lymphoma.  He also was a part of the T-PRC (translational project review committee) where research projects such as antibodies to prostate specific membrane antigen were evaluated to determine their ability to progress on to clinical trials.  Since joining the City of Hope he has been part of the Division and then Department of Radiation Oncology, the Department of Cancer Immunotherapeutics and Tumor Immunology, the Department of immunology and now the Department of Molecular Immunology.  Dr. Colcher has been involved in the submission and maintenance of over a dozen IND applications and clinical protocols. He is the co-scientific leader of the Theranostics Modality Team and is the Director of the Investigational Radiopharmacy as well as the Small Animal Imaging Core.  Dr. Colcher is involved in both preclinical and clinical theranostics studies in lymphoma as well as solid tumors.

Robert A. Copeland
President of Research and Chief Scientific Officer, Epizyme, Inc.

Robert A. Copeland, Ph.D. is President of Research and Chief Scientific Officer at Epizyme, Inc. He joined Epizyme in September 2008, from GlaxoSmithKline, where he was Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery. Dr. Copeland has also served on a number of advisory boards, committees and editorial boards in industry, academia, professional societies and professional journals. Before joining GSK he held scientific staff positions at Merck Research Laboratories, DuPont-Merck and Bristol-Myers Squibb and a faculty position at the University of Chicago, Pritzker School of Medicine. Dr. Copeland received his B.S. in chemistry from Seton Hall University, his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. His research interest is in elucidating the determinants of drug recognition by their biological targets, and the use of this information in the discovery and design of new medicines. A common theme throughout his research has been the role of protein dynamics in drug-target interactions.  In 2006 Dr. Copeland formulated the drug-target residence time model, a novel, alternative approach to drug optimization that has been widely adopted throughout the biotechnology and pharmaceutical industries. He has contributed to drug discovery and development efforts across multiple therapeutic areas, leading to 18 drug candidates entering human clinical trials. These include the cancer drugs foretinib, afuresertib, pinometostat, tazemetostat, Tafinlar (dabrafenib) and Mekinist (trametinib) and the antibiotic Altabax (retapamulin). Dr. Copeland has contributed more than 200 publications to the scientific literature, holds 13 issued U.S. patents and has authored 5 books in the areas of protein science and enzymology.

His most recent book, Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, 2nd Edition (Wiley, Hoboken, NJ), published in March 2013. In 2016 Dr. Copeland was elected a Fellow of the American Association for the Advancement of Science (AAAS).

Peter Kiener
Chief Scientific Officer, and Head of Research & Development, Sucampo Pharma Americs LLC

Dr. Peter A Kiener currently is a member of the Scientific Advisory Board of Mersana. He is currently the Chief Scientific Officer and Head of R&D at Sucampo Pharma Americs LLC.  Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates.  From 2009 to 2013, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company.  He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research.  Dr. Kiener previously worked on biologics for Bristol-Myers Squibb from 1983 to 2001. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983, and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982.  Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener currently serves as Chairman of the Board of Managers of Resolve LLC, and is a member of the Board of Directors of Cue Pharma LLC and Tetragenetics Inc .  He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.

K. Dane Wittrup
Professor of Chemical Engineering and Biological Engineering, MIT and Associate Director, Koch Institute

Prof. Dane Wittrup attended the University of New Mexico as an undergraduate, graduating Summa Cum Laude with a Bachelor’s in Chemical Engineering in June, 1984. Wittrup went on to attend the California Institute of Technology in Pasadena, where he worked with Prof. James Bailey on flow cytometry and segregated modeling of recombinant populations of Saccharomyces cerevisiae. After obtaining his Ph.D. in Chemical Engineering with a minor in Biology in 1988, he spent a brief time working at Amgen before becoming an Assistant Professor of Chemical Engineering at the University of Illinois at Urbana-Champaign in 1989. He moved to the Massachusetts Institute of Technology in September of 1999, where he is now the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, in addition to working with the Koch Institute as the Associate Director for Engineering.